secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viking Therapeutics, Inc. (VKTX)
CIK:        0001607678
Form:       8-K
Filed at:   2024-10-23T23:59:59+00:00
Accession:  0000950170-24-116642
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viking Therapeutics Q3 net loss $24.9M; cash $930M; pipeline advances with VK2735 and VK2809
--------------------------------------------------------------------------------

- Net loss of $24.9M ($0.22 per share) vs $22.5M loss in Q3 2023; R&D expense $22.8M.
- Cash and equivalents of $930M at Sept 30, 2024, up from $362M at Dec 31, 2023.
- End-of-Phase 2 meeting for subcutaneous VK2735 (obesity) planned for 4Q24; Phase 2 oral VK2735 trial expected to start 4Q24.
- Positive Phase 2b VOYAGE results for VK2809 in NASH/MASH with fibrosis selected for oral presentation at AASLD Nov 19.
- Positive Phase 1b results for VK0214 in X-ALD show reductions in very long-chain fatty acids and plasma lipids.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1607678/000095017024116642/0000950170-24-116642-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1607678/000095017024116642/vktx-20241023.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-116642

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer